Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $69.95 in the prior trading day, Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $69.28, down -0.96%. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 1.19 million shares were traded. SLNO stock price reached its highest trading level at $72.55 during the session, while it also had its lowest trading level at $69.06.
Ratios:
Our goal is to gain a better understanding of SLNO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.01 and its Current Ratio is at 15.13. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on October 07, 2025, initiated with a Buy rating and assigned the stock a target price of $125.
On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.
On June 23, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $110.TD Cowen initiated its Buy rating on June 23, 2025, with a $110 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 3681886208 and an Enterprise Value of 3447814144. For the stock, the TTM Price-to-Sale (P/S) ratio is 112.73 while its Price-to-Book (P/B) ratio in mrq is 14.55. Its current Enterprise Value per Revenue stands at 105.577 whereas that against EBITDA is -18.706.
Stock Price History:
The Beta on a monthly basis for SLNO is -2.92, which has changed by 0.24024343 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is 8.56%, while the 200-Day Moving Average is calculated to be 3.63%.
Shares Statistics:
The stock has traded on average 1.80M shares per day over the past 3-months and 1272000 shares per day over the last 10 days, according to various share statistics. A total of 50.44M shares are outstanding, with a floating share count of 46.01M. Insiders hold about 13.42% of the company’s shares, while institutions hold 96.85% stake in the company. Shares short for SLNO as of 1760486400 were 8435433 with a Short Ratio of 4.68, compared to 1757894400 on 7246780. Therefore, it implies a Short% of Shares Outstanding of 8435433 and a Short% of Float of 18.120001.
Earnings Estimates
The stock of Soleno Therapeutics Inc (SLNO) is currently drawing attention from 12.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.22, with high estimates of $0.62 and low estimates of -$0.41.
Analysts are recommending an EPS of between $0.24 and -$1.69 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is $3.04, with 12.0 analysts recommending between $5.56 and $1.01.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $62.84M. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $40.2M. Based on 11 analysts’ estimates, the company’s revenue will be $403.91M in the next fiscal year. The high estimate is $551.75M and the low estimate is $252.18M.
